Compumedics Adds $4.2m China MEG Order, Lifts Contracted Pipeline to $30m

Compumedics Limited ( (AU:CMP) ) just unveiled an announcement.

Compumedics has secured a new approximately $4.2 million order from Shandong Normal University in China for its Orion LifeSpan dual-helmet MEG system, including integrated CURRY neuro-imaging software and peripherals, placed via its long-standing Chinese distributor Beijing Fistar. This sixth Orion LifeSpan MEG sale lifts Compumedics’ total contracted MEG order book to about $30 million, reinforces its leadership in the technically demanding global MEG market, and extends revenue visibility well into FY27 as the system is delivered in line with production and site-readiness timelines. The deal underscores China’s role as a key growth market for advanced neuroscience infrastructure, adds to a growing installed base and reference sites, and supports Compumedics’ broader strategy of scaling its high-value MEG business alongside its sleep, neuro and SaaS platforms, with additional MEG opportunities progressing in China, North America and Europe.

The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.45 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.

More about Compumedics Limited

Compumedics Limited is an Australian-listed medical technology company specialising in neuro-imaging and related diagnostic systems, including magnetoencephalography (MEG) platforms. The company focuses on advanced brain imaging, sleep and neuro-diagnostic solutions, and SaaS platforms, targeting hospitals, research institutions and neuroscience centres globally, with China, North America and Europe as key growth markets.

Average Trading Volume: 91,010

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$89.89M

See more data about CMP stock on TipRanks’ Stock Analysis page.